Fusafungine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Fusafungine
Clinical data
SynonymsFusafungin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
DrugBank
UNII
KEGG
ECHA InfoCard100.014.306 Edit this at Wikidata
Chemical and physical data
FormulaC29H51N2O8
Molar mass555.72 g/mol[1]
 ☒N☑Y (what is this?)  (verify)

Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,[2] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.

According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.[3]

In February 2016, the European Medicines Agency recommended to withdraw fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).[4]

References[edit]

  1. ^ Fusafungine at MeSH
  2. ^ Daniel Levy; Aline Bluzat; Michel Seigneuret; Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12 22): 2105–2107. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
  3. ^ Lund, V. J.; Grouin, J. M.; Eccles, R; Bouter, C; Chabolle, F (2004). "Efficacy of fusafungine in acute rhinopharyngitis: A pooled analysis". Rhinology. 42 (4): 207–12. PMID 15626253.
  4. ^ PRAC recommends that fusafungine nose and mouth sprays are no longer marketed